Journal article icon

Journal article

The induction and maintenance of transplant tolerance engages both regulatory and anergic CD4+ T cells.

Abstract:
Therapeutic tolerance to self-antigens or foreign antigens is thought to depend on constant vigilance by Foxp3+ regulatory T cells (Tregs). Previous work using a pancreatic islet allograft model and a short pulse of CD3 antibody therapy has shown that CD8+ T cells become anergic and use TGFβ and coinhibitory signaling as their contribution to the tolerance process. Here, we examine the role of CD4+ T cells in tolerization by CD3 antibodies. We show that both Foxp3+ Tregs and CD4+ T cell anergy play a role in the induction of tolerance and its maintenance. Foxp3+ Tregs resisted CD3 antibody-mediated depletion, unlike intragraft Th1 CD4+ lymphocytes coexpressing granzyme B and Tbx21, which were selectively eliminated. Tregs were mandatory for induction of tolerance as their depletion at the time of CD3 antibody therapy or for a short time thereafter, by an antibody to CD25 (PC61), led to graft rejection. Early treatment with CTLA-4 antibody gave the same outcome. In contrast, neither PC61 nor anti-CTLA-4 given late, at day 100 posttransplant, reversed tolerance once established. Ablation of Foxp3 T cells after diphtheria toxin injection in tolerant Foxp3DTR recipient mice provided the same outcome. Alloreactive T cells had been rendered intrinsically unresponsive as total CD4+ or Treg-deprived CD4+ T cells from tolerant recipients were unable to mount donor-specific IFN-γ responses. In addition, intragraft Treg-deprived CD4+ T cells lacked proliferative capacities, expressed high levels of the inhibitory receptor PD-1, and exhibited a CD73hiFR4hi phenotype, thus reflecting a state of T cell anergy. We conclude that Tregs play a substantive and critical role in guiding the immune system toward tolerance of the allograft, when induced by CD3 antibody, but are less important for maintenance of the tolerant state, where T cell anergy appears sufficient.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.3389/fimmu.2017.00218

Authors

More by this author
Institution:
University of Oxford
Oxford college:
Lincoln College
Role:
Author


Dutch Kidney Foundation. More from this funder
University Paris Descartes More from this funder
Fondation Centaure More from this funder
Fondation Day Solvay More from this funder
Sixth Framework Programme More from this funder


Publisher:
Frontiers Media
Journal:
Frontiers in Immunology More from this journal
Volume:
8
Pages:
218
Publication date:
2017-03-01
Acceptance date:
2017-02-15
DOI:
EISSN:
1664-3224
Pmid:
28321218


Language:
English
Keywords:
Pubs id:
pubs:686993
UUID:
uuid:ecac5835-8e27-4394-addd-8d11848c882b
Local pid:
pubs:686993
Source identifiers:
686993
Deposit date:
2017-09-07
ARK identifier:

Terms of use


Views and Downloads

Views and downloads will return soon






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP